-

Aerin Medical Named Preferred Vendor for Radiofrequency Technologies by US ENT Partners

Leading ENT-focused group purchasing organization confirms Aerin's minimally invasive RF technology as its preferred solution for chronic rhinitis and nasal airway obstruction

MOUNTAIN VIEW, Calif. & PLANO, Texas--(BUSINESS WIRE)--Aerin Medical, the market leader in radiofrequency (RF) treatments for chronic nasal conditions, today announced a multi-year strategic partnership with US ENT Partners, the largest group purchasing organization (GPO) in otolaryngology. As part of the agreement, US ENT Partners has designated Aerin Medical as its preferred vendor for RF technology. VivAer and RhinAer are now recommended for use across the GPO's network of more than 1,500 physicians and 300 member practices.

The partnership meaningfully extends Aerin Medical's commercial reach, and positions both organizations to broaden awareness of RF-based treatment options for the millions of patients suffering from chronic rhinitis and nasal airway obstruction. The collaboration will leverage Aerin’s strong clinical and commercial foundation laid by over 40 peer-reviewed publications and more than 200,000 patients already treated with VivAer and RhinAer.

"Confirmation as US ENT Partners' preferred vendor for RF technologies is additional, meaningful validation of Aerin’s continued leadership," said Matt Brokaw, Chief Executive Officer of Aerin Medical. "This partnership creates a clear path for US ENT members to bring VivAer and RhinAer to their patients who need lasting relief, and underscores our mutual momentum."

"When our members evaluate a technology partner, they are looking for real innovation, a serious commitment to clinical evidence, and a field team they can rely on," said Keith Matheny, M.D., FARS, Founder, Chairman, and Chief Executive Officer of US ENT Partners. "Aerin Medical delivers on all three, and we are proud to bring the full value of the Aerin portfolio to our physician network."

About Aerin Medical

Aerin Medical is a privately held, venture-backed company headquartered in Mountain View, California. Aerin’s mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. Its products, VivAer® for nasal airway obstruction and RhinAer® for chronic rhinitis, use Aerin’s proprietary temperature-controlled radiofrequency technology to provide effective, minimally invasive alternatives to surgery. More than 200,000 patients have been treated with Aerin Medical products. For more information, please visit www.aerinmedical.com and follow Aerin Medical on Facebook, X, Instagram, LinkedIn and YouTube.

About US ENT Partners

US ENT Partners is the leading group purchasing organization serving the ENT specialty, supporting more than 1,500 physicians across 300-plus ENT, allergy, audiology, and sleep practices in all 50 states. Its consolidated vendor contracts, procurement technology, and revenue programs help independent and group practices operate efficiently and grow while maintaining their independence. For more information, visit www.usent.com.

Contacts

Media Contact
Shira Bernard
Aerin Medical
sbernard@aerinmedical.com

Aerin Medical


Release Versions

Contacts

Media Contact
Shira Bernard
Aerin Medical
sbernard@aerinmedical.com

More News From Aerin Medical

Aerin Medical Surpasses 200,000 Patients Treated with the Company’s Minimally Invasive Solutions for Chronic Nasal Conditions

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced that more than 200,000 patients have been treated with Aerin’s RhinAer® and VivAer® temperature- and impedance-controlled radiofrequency technologies, marking a significant milestone in the adoption of these practical solutions for minimally invasive nasal procedures. This achievement reflects the growing real-world impact of RhinAer and VivAer, as a...

Aerin Medical Launches Next-Generation Device for Chronic Rhinitis Relief

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced the launch of its next-generation RhinAer® device as well as UnitedHealthcare’s Medicare Advantage policy now covering RhinAer for treatment of the posterior nasal nerve (CPT 31242) effective immediately. The temperature- and impedance-controlled radiofrequency RhinAer+ device treats the posterior nasal nerve (PNN) and comprehensively targets multipl...

Three-Year Study Confirms Lasting Chronic Rhinitis Symptom Relief and Quality-of-Life Improvements with RhinAer®

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced the publication of long-term results from a multicenter study evaluating the safety and efficacy of RhinAer, which uses temperature-controlled radiofrequency (TCRF) to target the posterior nasal nerve (PNN) in patients with chronic rhinitis (CR). Published in the American Journal of Rhinology & Allergy, the study followed patients for three years...
Back to Newsroom